All In Biotech

Drug Trial Radar · NCT02767804

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Last checked: Nov 20, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

290

Actual

Start

Jun 2016

Primary completion

Dec 30, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Xcovery Holdings, Inc.Industry
Sponsor type
Industry
First posted
May 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • X-396 (ensartinib)Drug

    oral ALK inhibitor

  • crizotinibDrug

    oral ALK inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: 36 months

Locations

72 sites in 20 countries. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida

  • University Cancer & Blood Center

    Athens, Georgia

  • Washington University School of Medicine

    St Louis, Missouri

  • Providence Portland Medical Center

    Portland, Oregon

  • Sanatorio Parque S.A.

    Rosario, Argentina

  • Chris O Brien Lifehouse

    Camperdown, Australia

  • Border Medical Oncology Research Unit

    Albury, New South Wales, Australia

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • Catholic University of Louvain (UCL) - Site Mont Godinne

    Yvoir, Belgium

  • Hospital Haroldo Juaçaba - Instituto do Cancêr do Ceará

    Fortaleza, Brazil

  • Fundacao do ABC Faculdade de Medicina do ABC

    São Paulo, Brazil

  • Instituto do Câncer do Estado de São Paulo

    São Paulo, São Paulo, Brazil

  • Hospital de Câncer de Barretos - Fundação Pio XII

    São Paulo, São Paulo, Brazil

  • Infirmière recherche Clinique, IUCPQ

    Québec, Quebec, Canada

  • Peking University Cancer Hospital

    Beijing, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Beijing Chao Yang Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • Beijing Chest Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China

  • Guangdong General Hospital

    Guangzhou, Guangdong, China

  • Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Hunan Cancer Hospital

    Changsha, Hu'nan, China

  • Union Hospital of Tongji Medical College of Huazhong Science and Techology University

    Wuhan, Hubei, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Nanjing General Hospital

    Nanjing, Jiangsu, China

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • Vítkovická Nemocnice , a.s.

    Ostrava-Vitkovice, Czechia

  • Krajská zdravotní, a.s., Masarykova nemocnice

    Ústí nad Labem, Czechia

  • CHRU Lille

    Lille, France

  • Hopital Arnaud de Villeneuve

    Montpellier, France

  • CHU de Rennes Hôpital Pontchaillou

    Rennes, France

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.